News
British technology increases cervical cancer detection by up to 24 per cent
A new study, published by the European Journal of Obstetrics & Gynecology and Reproductive Biology, shows that use of a new British technology in diagnostic screening significantly increased the detection of cancer and potential cancer.
Scientists looked at the examination of 5257 women by 82 colposcopists in 26 clinics in nine different countries.
This new technology, called ZedScan and produced by Zilico Ltd, is a diagnostic system that is used alongside colposcopy to provide an objective assessment of the cervical epithelial tissue in real time.
The device uses EIS (Electrical Impedance Spectroscopy) technology to identify cell changes that cannot always be seen with standard colposcopy.

Colposcopy.
Following a service evaluation of over 200 patients, ZedScan increased the detection of high-grade disease (which has the potential to become cancerous) by 26 per cent. The high sensitivity of the device also gives clinical the confidence to discharge women to surveillance or routine screening when no high-grade disease is indicated.
Used by many NHS Trusts and hospitals in Finland, the advanced diagnostic tool will help provide better outcomes for women across the globe.
Sam Kothari, CEO at Zilico Ltd, said “It is fantastic news for patients in the UK and further afield. The publication shows how ZedScan help across different clinical settings in nine countries.
Colposcopy has not materially changed for nearly 100 years and this data shows how having this advanced technology at the point of examination during colposcopy helps patients, clinicians and hospitals.”
“Not only is this technology meaningful for the patient’s comfort and reassurance it is quite simply detecting more problems accurately, and in greater detail, allowing people to access the treatment that they need more efficiently,” he added. “This is important research here in the UK and Europe, and moreover has huge potential for the rest of the world and developing economies where cervical cancer goes readily undetected.”

Cervical cancer development.
According to Cancer Research UK, cervical cancer affects 3,197 women each year in the UK with a survival percentage of 51.
Cervical cancer is a cancer that’s found anywhere in the cervix. Nearly all cervical cancers are caused by an infection from certain types of human papillomavirus (HPV). This type of cancer can often be prevented by attending cervical screening, which aims to find and treat changes to cells before they turn into cancer.

Some cervical cancer symptoms to look out for.
The cervical screening process screens for HPV infection and those with HPV are referred for colposcopy. In addition to traditional colposcopy methods many NHS trusts have started using ZedScan for improved diagnostic information provided in real-time.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Wellness4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Hormonal health3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Hormonal health5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







4 Comments